Vlado Perkovic's Publications

Li C, Yu J, Hockham C et alii
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis
Journal articles
2022
Diabetes
Nazarzadeh M, Bidel Z, Canoy D et alii
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
Journal articles
2022
The Lancet Diabetes and Endocrinology
Koshino A, Schechter M, Sen T et alii
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.
Journal articles
2022
Diabetes Care
Li JW, Arnott C, Heerspink HJL et alii
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
Journal articles
2022
Journal of the American Heart Association
Ridker PM, Tuttle KR, Perkovic V et alii
Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy.
Journal articles
2022
Eur Heart J
Ferrannini E, Baldi S, Scozzaro T et alii
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)
Journal articles
2022
Diabetes care
Heerspink HJL, Stack AG, Terkeltaub R et alii
Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia
Journal articles
2022
Nephrology
Kotwal S, Perkovic V, Heerspink HJL
Platform Clinical Trials Within Nephrology—Interpreting the Evidence
Journal articles
2022
American Journal of Kidney Diseases
Smeijer JD, Koomen J, Kohan DE et alii
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure
Journal articles
2022
JACC: Heart Failure
Liao J, Kang A, Xia C et alii
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial
Journal articles
2022
Diabetes and Metabolism
PRATLEY RE, BAERES FMM, BAKRIS G et alii
747-P: Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial
Conference Presentations
2022
Vol. 71
KOSHINO A, SCHECHTER M, SEN T et alii
862-P: Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial
Conference Abstracts
2022
in Diabetes
Singh AK, Cizman B, Carroll K et alii
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial
Journal articles
2022
JAMA Internal Medicine
Barraclough JY, Yu J, Figtree GA et alii
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial
Journal articles
2022
Diabetes
Waijer SW, Provenzano M, Mulder S et alii
Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology
Journal articles
2022
Diabetes
Lv J, Wong MG, Hladunewich MA et alii
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial
Journal articles
2022
JAMA - Journal of the American Medical Association
Neuen BL, Oshima M, Agarwal R et alii
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized, Controlled Trials
Journal articles
2022
Circulation
Perkovic V, Baeres F, Bakris G et alii
FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease
Conference Abstracts
2022
in Nephrology Dialysis Transplantation
Singh AK, Blackorby A, Cizman B et alii
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial
Journal articles
2022
Nephrology Dialysis Transplantation
Feng Y, Li Q, Finfer S et alii
A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation
Journal articles
2022
Frontiers in Cardiovascular Medicine
Shaman AM, Bain SC, Bakris GL et alii
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Journal articles
2022
Circulation
Waijer SW, Sen T, Arnott C et alii
Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease
Journal articles
2022
Clinical Journal of the American Society of Nephrology
Heerspink HJL, Oshima M, Zhang H et alii
Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial
Journal articles
2022
American Journal of Kidney Diseases
Liyanage T, Toyama T, Hockham C et alii
Prevalence of chronic kidney disease in Asia: A systematic review and analysis
Journal articles
2022
BMJ Global Health
Perkovic V, Blackorby A, Cizman B et alii
The ASCEND-ND trial: study design and participant characteristics
Journal articles
2022
NEPHROLOGY DIALYSIS TRANSPLANTATION
Shah N, Perkovic V, Kotwal S
Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria
Journal articles
2022
Expert Review of Clinical Pharmacology

Vlado Perkovic's Publications

Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy.

Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)

Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia

Platform Clinical Trials Within Nephrology—Interpreting the Evidence

Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure

The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial

747-P: Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial

862-P: Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial

Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial

Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial

Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology

Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized, Controlled Trials

FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease

Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial

A Novel Risk Prediction Model for Severe Acute Kidney Injury in Intensive Care Unit Patients Receiving Fluid Resuscitation

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease

Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial

Prevalence of chronic kidney disease in Asia: A systematic review and analysis

The ASCEND-ND trial: study design and participant characteristics

Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country